Details for New Drug Application (NDA): 050724
✉ Email this page to a colleague
The generic ingredient in ABELCET is amphotericin b. There are fifteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the amphotericin b profile page.
Summary for 050724
| Tradename: | ABELCET |
| Applicant: | Leadiant Biosci Inc |
| Ingredient: | amphotericin b |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050724
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE, LIPID COMPLEX;INJECTION | Strength | 5MG/ML | ||||
| Approval Date: | Nov 20, 1995 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 050724
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Leadiant Biosci Inc | ABELCET | amphotericin b | INJECTABLE, LIPID COMPLEX;INJECTION | 050724-001 | Nov 20, 1995 | 5,616,334 | ⤷ Start Trial |
| Leadiant Biosci Inc | ABELCET | amphotericin b | INJECTABLE, LIPID COMPLEX;INJECTION | 050724-001 | Nov 20, 1995 | 6,406,713 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
